arrow
T

Teerapat Ungtrakul

chulabhorn royal academy
H指数:16
被引数:1,250

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase 2 trial

Savolitinib 联合 Osimertinib 治疗表皮生长因子突变、MET 扩增的晚期非小细胞肺癌:一项随机 II 期临床试验

2025-10-220
PRE
The landscape of etiological patterns of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Thailand
2024-05-186
OA
Savolitinib (savo) plus osimertinib (osi) vs savo plus placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi
2024-04-050
PRE
Pan-viral serology uncovers distinct virome patterns as risk predictors of hepatocellular carcinoma and intrahepatic cholangiocarcinoma
2023-12-015
OAAI
Gut dysbiosis in Thai intrahepatic cholangiocarcinoma and hepatocellular carcinoma
2023-07-149
OAAI
Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10-17 Years in Thailand

泰国10-17岁青少年使用bbibp-corv (国药) 新型冠状病毒肺炎疫苗后的安全性

2022-10-2112
OAAI
Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study

泰国人群中bbibp-corv疫苗在12至17岁青少年中的安全性和免疫原性: 一项免疫印迹研究

2022-05-194
OAAI
Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine
2022-04-017
PRE
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients
2021-01-0417
PREAI
Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients
2020-09-0120
OAAI